SAMANTHA GRIFFIN: Open Payments
NPI 1316572951 · CHARLOTTE, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,903 in 155 payments from 19 companies in 2025. Trend: 2023 $2,674 · 2024 $2,584 · 2025 $3,903
Food & beverage: $3,633Education: $201Consulting: $69
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 21 | $848 |
| ARS Pharmaceuticals Operations, Inc. | 30 | $514 |
| Novartis Pharmaceuticals Corporation | 19 | $497 |
| AstraZeneca Pharmaceuticals LP | 21 | $434 |
| CSL Behring | 15 | $409 |
| GENZYME CORPORATION | 3 | $175 |
| Incyte Corporation | 2 | $163 |
| GlaxoSmithKline, LLC. | 11 | $159 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $157 |
| BioCryst US Sales Co., LLC | 6 | $141 |
Products named: DUPIXENT, NEFFY, Andembry, TEZSPIRE, Rhapsido, FASENRA, AIRSUPRA, Hizentra.
Industry payments across NC — which companies pay providers there.
